title: Effect of isotretinoin on endogenous tissue-type plasminogen activator (t-PA) and plasminogen activator inhibitor 1 (PAI-1) in humans.
abstract: The effect of isotretinoin on fibrinolysis was investigated in 10 healthy, male volunteers in a randomized, double-blind, crossover-designed study. Isotretinoin (40 mg) was administered in the morning and in the evening for 5 days. t-PA, u-PA and PAI-1 antigen and activity in plasma were measured every morning at 9 a.m. on days 1 to 4 and every 3 hours over 24 hours on day 5. Isotretinoin treatment had no significant stimulatory effect on endogenous t-PA antigen and activity in morning plasma samples nor on their circadian variation. Also, u-PA antigen levels did not change after isotretinoin treatment. Mean PAI-1 antigen and PAI activity in 9 a.m. plasma samples were non-significantly higher during isotretinoin than during placebo treatment. After treatment with isotretinoin a significant rise of fasting triglyceride plasma levels was observed as compared to placebo. The study shows that isotretinoin has no clinically significant effect on endogenous fibrinolysis.
authors.affiliation: Centre for Human Drug Research, University Hospital Leiden, The Netherlands.
authors.forename: A E
authors.initials: AE
authors.lastname: Wallnöfer
authors.forename: J M
authors.initials: JM
authors.lastname: van Griensven
authors.forename: H C
authors.initials: HC
authors.lastname: Schoemaker
authors.forename: A F
authors.initials: AF
authors.lastname: Cohen
authors.forename: W
authors.initials: W
authors.lastname: Lambert
authors.forename: C
authors.initials: C
authors.lastname: Kluft
authors.forename: P
authors.initials: P
authors.lastname: Meijer
authors.forename: T
authors.initials: T
authors.lastname: Kooistra
mesh_terms: D000328:Adult; D000941:Antigens / Q000097:blood; D004311:Double-Blind Method; D006801:Humans; D015474:Isotretinoin / Q000494:pharmacology*; D008297:Male; D017395:Plasminogen Activator Inhibitor 1 / Q000097:blood* / Q000276:immunology; D012016:Reference Values; D010959:Tissue Plasminogen Activator / Q000187:drug effects* / Q000276:immunology; D014568:Urokinase-Type Plasminogen Activator / Q000276:immunology
chemical_list: D000941:Antigens; D017395:Plasminogen Activator Inhibitor 1; D010959:Tissue Plasminogen Activator; D014568:Urokinase-Type Plasminogen Activator; D015474:Isotretinoin